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CuCl inhibition of G6PD in normal red blood cells (RBCs) to assess G6PD diagnostic
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G6PD, CSG) against FST using graded CuCl treatments to simulate variable hemizy-
gous states, and varying proportions of CuCl-treated RBC suspensions to simulate
variable heterozygous states of G6PD deficiency. In experiments double-blinded
to CuCl treatment, technicians reading FST and CSG test (n 5 269) classified results
as positive or negative for deficiency. At G6PD activity #40% of normal (n 5 112),
CSG test was not inferior to FST in detecting G6PD deficiency (P 5 0.003), with 96%
vs 90% (P 5 0.19) sensitivity and 75% and 87% (P 5 0.01) specificity, respectively.
The CSG test costs less, requires no specialized equipment, laboratory skills, or
cold chain for successful application, and performs as well as the FST standard of
care for G6PD screening. Such a device may vastly expand access to primaquine
therapy and aid in mitigating the very substantial burden of morbidity and mortality
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AT A GLANCE COMMENTARY
Baird JK, et al.
Background
Plasmodium vivax threatens 2.5 billion and causes
.100 million clinical attacks, most originating
from untreated forms in the liver. These are rarely
treated because the only drug, primaquine, causes
threatening acute hemolytic in patients having an
inborn deficiency in glucose-6-phosphate dehydro-
genase (G6PD).
Translational Significance
 We affirm noninferiority of a potentially
important new clinical instrument—a G6PD
deficiency test suitable for use where most pa-
tients with malaria live—compared with the
laboratory standard test.
 We detail a novel laboratory technique for
such evaluations—copper inhibition of G6PD
in normal red blood cell modeling the full
range of phenotype heterogeneity among hem-
izygotes and heterozygotes.
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More than 2.5 billion people live at risk of infection
by the blood parasite Plasmodium vivax, and more
than a hundred million suffer clinical attacks every
year.1,2 Although long viewed as a relatively benign
infection, reports and studies from endemic areas and
in travelers over the past decade reveal an often
pernicious and sometime fatal course associated with
a diagnosis of vivax malaria.3,4 This understanding
has focused renewed emphasis and interest on long-
neglected clinical and public health issues regarding
this infection, especially the very difficult problem of
glucose-6-phosphate dehydrogenase (G6PD) deficiency
and primaquine therapy.5
The main clinical and public health problem is the
ability of P. vivax to place dormant forms in the liver
called hypnozoites. These parasites typically cause 3
or more clinical attacks in relatively quick succession
in the months after the primary attack, or may do so
up to 1 or 2 years later.6 Some heavily exposed patients
suffer up to 20 distinct hypnozoite-borne attacks of vi-
vax malaria within 2 years.7 Among cohorts in Thailand
and Indonesia, the incidence density of first relapse in
the 2 months after a primary attack was about 5/per-
son-year.8-10 Such attack rates approximate those of
Plasmodium falciparum in the highest risk zones of
sub-Saharan Africa.11 Failure to prevent relapse in vivaxmalaria results in very high risk of debilitating illness of
deepening seriousness and opportunities for onward
transmission to others. Nonetheless, most patients diag-
nosed with vivax malaria do not receive therapy against
relapse as a consequence of the rational fear of causing
serious harm with primaquine among unscreened pa-
tients with G6PD deficiency.5
Among the many drugs available to treat the acute
attack of vivax malaria, none affect the latent hypno-
zoites.12 The only drug registered as safe and effective
in preventing relapses is primaquine, and it has been
in continuous use since 1952. At therapeutic dosing
against relapse, primaquine causes a mild to severe
acute hemolytic anemia in patients having an inborn
deficiency of G6PD.13,14 This extraordinarily diverse
and complex X-linked trait occurs most frequently
where there is endemic malaria transmission, as it
may confer some protection against the onset of
severe and threatening malaria.15 About 400 million
people are affected, with an average prevalence of
G6PD deficiency in malaria endemic nations of about
8%.16 The blind administration of primaquine to pa-
tients diagnosed with vivax malaria is often rationally
considered unacceptably hazardous or reckless by pro-
viders of malaria treatment services. In impoverished
rural settings, patients very often are not provided pri-
maquine therapy as a direct consequence of a lack of ac-
cess to G6PD screening.
G6PD deficiency as the basis of hemolytic sensi-
tivity to primaquine was described in 1956,17 and a
variety of diagnostic tests for the disorder appeared
within a decade. One of the most widely recommended
and used has been the fluorescent spot test (FST)
described in 1966 by hematologist and pioneering
G6PD scientist Ernest Beutler.18 It has seen several de-
cades of practical and safe use in the developed world,
but finds almost no routine application where most
patients with malaria live. The reasons include cost,
specialized equipment, laboratory skills, temperature
sensitivity, and a cold chain for the reagents. Any
one of those pitfalls may suffice to prohibit routine
use in impoverished tropical settings. The combination
of them explains more than 50 years without access to
G6PD screening, which in turn accounts for the lack of
access to primaquine therapy against vivax malaria for
almost all those patients. We consider this deceptively
simple problem the likely basis of most clinical attacks
of vivax malaria and attendant burdens of morbidity
and mortality.
In the present study, we conducted a laboratory-based
evaluation of the performance of a new G6PD screening
device that appears to have overcome the obstacles to
practical use where most patients with malaria live.
The CareStart G6PD kit (CSG; AccessBio Inc, New
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chain, or controlled temperature setting. A result is
rendered within 10 minutes. The kit sells for $1.50
per test. We reasoned that practical point-of-care quali-
tative screening for G6PD byCSG should be noninferior
to the FST in red blood cells (RBCs) exhibiting variable
levels of residual G6PD activity after being incuba-
ted with the G6PD inhibitor CuCl. After optimizing
that inhibition, we designed and executed a series of
double-blinded experiments to assess the noninferio-
rity of CSG to FST using simulated G6PD-deficient
RBCs for both hemizygous and heterozygous states.
We aimed this work at generating the evidence needed
to inform decisions for investment in more ambitious
evaluations in patients in rural tropical settings.MATERIALS AND METHODS
G6PD quantitative assay. The quantitative assay for
erythrocytic G6PD activity in hemolysate was per-
formed using the commercial kit from Trinity Biotech
(Ireland) as catalog number (cat#) 345-B. The
manufacturer’s instructions were followed. In brief,
substrate of glucose-6-phosphate and cofactor
nicotinamide adenine diphosphate, NADP1, was
reconstituted with sterile double-distilled water and
2 mL added to 1 mL of hemolysate reaction buffer
(provided by the manufacturer). Then, 10 mL of whole
blood collected in acid citrate dextrose (ACD) tubes
(BD Vacutainer ACD Solution A; Becton-Dickinson)
was added to the 3 mL mixture. The tube was
incubated at 30C for 5 minutes and its absorbance at
340 nm wavelength was measured on an ultraviolet
spectrophotometer (Biowave II; Biochrome) and
recorded as ‘‘initial’’ absorbance optical density. An
additional 5 minutes in the 30C water bath was
followed by another absorbance measurement
recorded as ‘‘final.’’ Hemoglobin levels on all venous
blood samples were measured using a clinical blood
analyzer (Abbott Cell Dyne CD1700). These values
were applied to calculate the international units of
enzyme activity per gram hemoglobin as per the
manufacturer’s instructions.
In accordance with the Code of Ethics of the World
Medical Association expressed in the Declaration of
Helsinki, each collection of blood in these experiments
was done with the signed, informed consent of the 2
G6PD normal subjects involved under a protocol for
such collections that was reviewed and approved by
the Ethics Review Board of the Eijkman Institute for
Molecular Biology.
Optimizing CuCl inhibition of RBCG6PDactivity. Copper
inhibits G6PD activity,19 but no work yet described
optimized inhibition in intact RBC suspensions. Weevaluated quantitative G6PD activity in hemolysate
prepared from intact RBCs incubated with copper
under a variety of conditions, including anticoagulant,
RBC preparation (whole blood, packed RBCs, or
hemolysate), incubation time (in a 37C water bath for
1, 2, 3, or 24 hours), copper ion (CuCl from Fluka cat#
00664 vs CuSO4), and wide ranges of copper
concentration (1 nM–0.1 M). We found whole blood
collected with ACD anticoagulant and incubated with
final concentrations of 0.2–1.0 mM CuCl (1:9 vol/vol
CuCl solution in water to whole blood) for 24 hours
at 37C consistently inhibited G6PD activity in
a dose-dependent manner by up to 95%. The
concentrations of CuCl reported represent those in the
final suspension of whole blood with CuCl. These
conditions of CuCl treatment represent the
experiments detailed in this report.
Modeling variation in hemizygousmales ormosaicism in
heterozygous females. As an X-linked trait, G6PD defi-
ciency occurs in males only in the hemizygous state,
that is, the lone X chromosome is either G6PD wild
type or mutant, and all RBCs will express either normal
or deficient phenotypes. The heterogeneity of G6PD ac-
tivity among hemizygotes ranges from nearly normal to
barely detectable.20 We modeled this heterogeneity
among male hemizygotes by treating RBCs with
variable concentrations of CuCl, where all RBCs in
the suspension had impaired G6PD activity.
Females, in contrast, possess 2 X chromosomes
that may be wild type:wild type, wild type:mutant, or
mutant:mutant (wild type, heterozygous, and homozy-
gous, respectively). The heterozygotes pose a particular
diagnostic problembecause of the lyonization of the trait
during random inactivation of 1 X chromosome during
embryonic development.21 This results in RBCs of indi-
vidual females expressing either fully normal or fully
deficient phenotypes in a mosaic of fixed proportions
ranging between 0% and 100%. We modeled this
mosaicism among female heterozygotes by mixing var-
iable proportions of untreated and 1.0 mM CuCl-treated
RBCs for diagnostic evaluation. Homozygous females
have 100% deficient RBC populations and were
effectively represented by the hemizygous model.
G6PD qualitative assays. Two commercially available
qualitative G6PD deficiency screening kits were used
in the experiments: (1) G-6-PDH, cat# 203-A from
Trinity Biotech, Bray, Ireland and (2) CareStart G6PD,
cat# G0221 from AccessBio (Somerset, New Jersey).
Henceforth, these kits will be referred to as FST and
CSG, respectively, throughout this report. The kits
have been used as per manufacturer’s instructions.
The FST was always executed with 3 G6PD controls
sold separately by the manufacturer (Trinity Biotech):
(1) G6PD normal control (cat# G6888); (2) G6PD
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control (cat# G5888). In brief, the FST involved
placing 10 mL whole blood into the manufacturer’s
hemolyzing (0.2% saponin) buffer containing NADP1
cofactor and glucose-6-phosphate substrate and placed
into a 37C water bath. Aliquots of 20 mL were taken
and placed onto filter paper at designated intervals.
The dried filters (about 30 minutes) were read under
ultraviolet light within a few minutes in a dark room.
G6PD normal hemolysate on filter paper fluoresced
brightly (by the dominance of nicotinamide adenine
diphosphate), whereas G6PD-deficient hemolysate
remained dark (by the dominance of NADP1). Fig 1
illustrates this distinction in color development.
The CSG involved placing 2–3 mL whole blood into a
receptacle within a plastic cassette, followed by a few
drops of hemolyzing reaction buffer provided with the
kit. The cassette was visually read after standing 10 mi-
nutes at room temperature. Development of a distinct
purple color in the cassette window represented a nega-
tive test outcome, whereas development of no color, or
color distinctly lighter than most others, constituted evi-
dence of a positive test outcome, that is, positive for
G6PDdeficiency. Fig 1 illustrates this distinction in color
development. The CSG is composed of a cellulose strip
impregnatedwith theG6P substrate ofG6PDanda color-
less tetrazolium compound salt (patent pending). Reduc-
tion of that compound yields a purple formazan dye. In
the strip containing hemolysate and G6P substrate, the
extent of reduction depends onG6PD activity. The pack-
age insert for this product specifies that a tested concen-
tration of 0.156 mM (2.5 mg/dL) CuCl did not impact
with the assay system. The highest final concentration
of CuCl in the G6PD activity assays did not exceed
0.04 mM (after dilution of RBC suspension in lysates).
We thus considered CuCl interference in the assays by
direct redox disturbance (as opposed to its known
G6PD enzyme inhibitory properties) very unlikely.
A total of 9 separate experiments over the course of
several months using 2 known G6PD normal blood do-
nors were conducted (see Fig 2). On each occasion a
suspension of 0.45 mL whole blood mixed with
0.05 mL water served as the normal (no CuCl) G6PD
activity control. In the case of the hemizygote model,
5 other tubes contained the same except with the addi-
tion of CuCl to water to provide final whole blood sus-
pension of CuCl concentrations of 0.2, 0.4, 0.6, 0.8, and
1.0 mM. In the case of the heterozygote model, blood
was incubated with 1.0 mM CuCl in water or water
only. These were placed in a 37C water bath and incu-
bated for 24 hours.
After gentle mixing, these tubes were immediately
treated essentially as whole blood in the conduct of
the quantitative and qualitative G6PD assays as outlinedpreviously in accordance with the standard instructions.
In case of the hemizygote model, single tubes represent-
ing each of the inhibition treatments were aliquoted into
5 tubes. Each of those tubes was then used for all 3 of the
G6PD assays that immediately followed: quantitative,
FST, and CSG. Each of these 6 experiments thus gener-
ated 30 measurements of G6PD activity, 30 FST read-
ings, and 30 CSG readings, or a total of 180 each. In
the heterozygote model, each of the 10 distinct CuCl
treatments (see Fig 2) were aliquoted into 3 vials,
each generating a separate G6PD assessment, or 30
for each of the 3 separate experiments for a total of 90
assessments. In all, 270 separate assessments were con-
ducted for each of the 3 distinct G6PD assays in both
models. A single treatment tube evaluated by all 3 tests
was rejected as flawed: a G6PD activity value of 0.5 U/
gHb was read as negative for G6PD deficiency by both
FST and CSG, and we considered this lone set an error
of treatment or labeling in excluding it from the ana-
lyses reported here. Thus, the total sample evaluated
was 269 for each of the 3 methods of G6PD assessment.
Double-blinded reading of qualitative assays. Assay of
quantitative and qualitative G6PD in the blood treat-
ments was carried out immediately after the 24 hours
of incubation with CuCl or water. A technician not
involved in the assays removed the tubes from the water
bath and covered them with opaque tape, recording an
identity unrelated to CuCl treatment. All results were re-
corded by that identity. The blinded tubes were taken to
the laboratory for carrying out the G6PD quantitative
assays and required aliquots were removed, followed
by the same for the 2 separate laboratories doing the
FSTand CSG screening. These 2 laboratories alternated
conduct of the FST and CSG on each of the separate
days of experiments represented in this report.
All the 6 technicians involved in the qualitative test
analysis were trained in doing so beforehand. The
training included prohibition on classifying a test
outcome as intermediate or indeterminate based on par-
tial color development alone. The demand was made to
decide on ‘‘positive’’ or ‘‘negative’’ (deficient or
normal), with clear instructions to consider noticeably
diminished color development relative to normal control
as positive. We considered this approach appropriate for
the intended use of the kits, that is, in guiding a decision
to apply primaquine therapy, in which a classification of
an ‘‘intermediate’’ as positive for deficiency errs in favor
of the safety of the patient. Further, instruction to
consider the development of color of any intensity as
negative likely leads to underestimation of the sensi-
tivity of G6PD deficiency screening.22
Assessment of CSG noninferiority to FST. The statistical
analysis of this study applied the methods of testing
equivalence or noninferiority essentially as described
Fig 1. Photographs illustrating the visual read of the G6PD screening devices according to the intensity of color
development.
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sensitivity and specificity for diagnostic devices suffer
the drawback imposed by broad heterogeneity of
G6PD activity (both in the experimental model and in
patients). There is uncertainty of the threshold of that
activity for safety with a decision to proceed with
primaquine therapy. In other words, the simple
dichotomy of positive or negative test outcomes
underpinning the mathematical treatment of sensitivity
and specificity estimates imposes real uncertainty in
the context of G6PD deficiency and primaquine
safety. Statistical testing for noninferiority largely
solved these problems.
Conventional hypothesis testing statistics evaluate
differences between groups. Typically, P value esti-
mates ,0.05 reflect statistical significance of differ-
ence, and those .0.05 indicate a lack of difference, or
statistical sameness. The test of noninferiority does
not rely on P values.0.05, largely because such values
may simply be a product of insufficient power to discern
real difference. The statistical treatment for noninferior-
ity averts such possible ambiguity by instead assigning
P values ,0.05, where there is genuine, adequately
powered equivalence or noninferiority. The noninferior-
ity testing reported here applied an alpha of 5%, a 90%
confidence interval, and a noninferiority margin of 5%.
The statistical analysis of noninferiority combined
the screening test outcomes from both the male hemizy-
gous and female heterozygous models. We reasoned
that the percent of normal G6PD activity in the RBCsuspension as a whole, regardless of the means of its
compromise, represented the key determinant of diag-
nostic performance. Noninferiority of CSG to FST
was assessed at discrete levels of residual G6PD activ-
ity, a key advantage of the CuCl model over naturally
G6PD-deficient RBCs for this purpose.
Assessment of sensitivity and specificity of FST and
CSG. We examined the diagnostic performance of the
FST and CSG relative to quantitative G6PD activity us-
ing standard estimates of sensitivity, specificity, positive
predictive value, and negative predictive value for each.
This approach required establishing a firm threshold of
G6PD activity for positivity for G6PD deficiency. We
chose #40% of normal values as the threshold. We
reasoned that hemizygotes having higher levels than
this threshold could safely receive primaquine therapy.
However, it is acknowledged that such a threshold is
not grounded in sufficient clinical evidence, and it
may not apply to heterozygous females for the complex
reasons explained. Nonetheless, these diagnostic perfor-
mance characteristics provide a useful, even if strictly
limited, metric of diagnostic performance in the context
of screening for primaquine therapy.RESULTS
G6PD quantitative activity with CuCl treatment. The 5
treatments with CuCl (0.2, 0.4, 0.6, 0.8, and 1.0 mM)
modeling hemizygous states resulted in levels of
G6PD inhibition ranging from slight with 0.2 mM
Fig 2. Diagram illustrating 9 separate experiments and the course of treatment with copper chloride before
blinded diagnostic evaluation by 3 distinct devices; quantitative, and 2 qualitative tests, the CareStart G6PD
(CSG) and fluorescent spot test (FST). The representations of tubes under donor blood indicate experiments on
different days. The tubes showing CuCl treatments from 0 to 1.0 mM (top) represent a set of 5 replicates each
for each separate experiment (#1–#6). The tubes showing %CuCl treated from 1% to 100% (bottom) each repre-
sent a set of triplicates for each of the experiments conducted (#7–#9).
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values represented a continuum between 138% (9.6 U/
gHb) and 5% (0.4 U/gHb) of the mean value from sam-
ples not exposed to CuCl (6.9 U/gHb) in that series.
A similar continuum of G6PD activity occurred
among the variable proportions of CuCl-treated
(1.0 mM) RBC modeling heterozygous states. The
mean-untreated G6PD activity was 7.8 U/gHb in that
series and ranged between 10.8 and 0.8 U/gHb
(138%–10% of normal, respectively).
Noninferiority analysis of CSG to FST. The analysis of
noninferiority of CSG to FST treated G6PD activity as
a continuous variable rather than according to groups
of CuCl treatment. Table I lists the results of this
analysis. Qualitative test outcomes were pooled into
groups according to percent of normal G6PD activity
in increments of 10 percentiles and each statistically
analyzed for noninferiority. At all levels of G6PDactivity except the lowest and highest increments
(which were inconclusive because of inadequate
sample size), the diagnostic performance of the CSG
was not inferior to the FST, with P values ranging
from 0.006 to ,0.001.
Fig 3 illustrates all these test outcomes grouped in in-
crements of 0.25 U/gHb. The graphic visualizes the gen-
eral equality in G6PD detection across the range of
G6PD activity levels. The lateral dotted line in the
graphic represents the cutoff of 40% of normal G6PD
activity applied to separate those positive or negative
for G6PD deficiency. The graphic also shows the
slightly lower frequency of false negatives among
CSG, and the higher frequency of false positives, espe-
cially at levels immediately higher than 40% of normal
G6PD activity.
Sensitivity and specificity of the FST and CSG. Table II
lists the test outcomes and statistics for the sensitivity
Table I. Table lists G6PD screening test outcomes at various thresholds of G6PD inhibition and the statistical noninferiority statistics of CSG vs FST at each
level
% Normal G6PD activity Test type Test positive for deficiency Test negative for deficiency Number of tests % Positive for deficiency P value Result
#20% FST 30 1 31 97% 0.058 Inconclusive
CSG 31 0 31 100%
#30% FST 75 3 78 96% 0.006 Not inferior
CSG 77 1 78 99%
#40% FST 101 11 112 90% 0.003 Not inferior
CSG 107 5 112 96%
#50% FST 117 33 150 78% 0.001 Not inferior
CSG 131 19 150 87%
#60% FST 119 60 179 67% 0.001 Not inferior
CSG 137 42 179 77%
#70% FST 121 81 202 60% 0.001 Not inferior
CSG 142 60 202 70%
#80% FST 121 97 218 56% ,0.001 Not inferior
CSG 145 73 218 67%
#90% FST 122 110 232 53% 0.001 Not inferior
CSG 146 86 232 63%
#100% FST 122 124 246 50% 0.001 Not inferior
CSG 146 100 246 59%
.100% FST 0 23 23 0% 0.443 Inconclusive
CSG 0 23 23 0%
Abbreviations: CSG, CareStart G6PD; FST, fluorescent spot test; G6PD, glucose-6-phosphate dehydrogenase.
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Fig 3. Scatter plot illustrates individual screening test outcomes by
qualitative fluorescent spot test (FST, to left) or CareStart G6PD
(CSG, to right) at 2.5% of normal increments of G6PD activity (y-
axis) among all tests conducted (n 5 269 each), where black circles
indicate a reading as positive for G6PD deficiency, and the white cir-
cles indicate a negative reading. The horizontal dashed line across the
graph represents the 40% cutoff adopted in this study for separating
G6PD-deficient and normal activity levels.
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of normal G6PD activity as the threshold of positivity
for G6PD deficiency. The analysis tends to affirm the
trends seen in the scatter plot of Fig 3, that is, equality
of sensitivity in the FST and CSG (90% vs 96%;
P 5 0.19) and lesser specificity in the CSG (89% vs
75%; P 5 0.01). In brief, the CSG performed as well
as the FST in detecting G6PD deficiency at #40% of
normal, but more often misclassified higher levels of
activity as positive for deficiency.
CSG and FST positivity in simulated hemizygote and
heterozygote states. Figs 4 and 5 illustrate FST and
CSG positivity across the range of G6PD activity
levels that naturally occur among patients in both the
hemizygous and heterozygous states. The essentially
similar findings across CuCl treatments (either
variable concentrations or variable proportions of
treated RBCs) affirm the dependence of qualitative
diagnostic outcomes on net G6PD activity in RBC
suspensions. In other words, the presence of
uninhibited G6PD enzyme did not overcome the
effects of variable proportions of CuCl-inhibited
G6PD enzyme. The model suggests that hemizygotes
and heterozygotes will test as G6PD deficient
depending on the same net G6PD activity level,
whether because of all RBCs being inhibited or some
proportion of them.
Findings in the experiments modeling the heterozy-
gous state model suggest that both the FST and CSG
will perform inconsistently between the range of 40%and 70% of RBCs being G6PD deficient (at the approx-
imately 10% of normal activity with 1.0-mM CuCl
treatment). The odds of being classified as deficient
increased in proportion to the diminishing net G6PD ac-
tivity within that range.DISCUSSION
The laboratory findings reported here demonstrate
noninferiority of a point-of-care screening device for
G6PD deficiency (CSG) compared with a screening
kit routinely used in the laboratory (FST). CSG has
the enormous advantage over FST of appearing suitable
for use in the impoverished rural tropics. The successful
distribution and use of such a device may finally provide
access to antirelapse therapy with primaquine to mil-
lions of patients otherwise suffering repeated attacks
of acute vivax malaria. Definitive validation of that suit-
ability and adequate diagnostic performance must await
large scale, real world assessments in patients with
G6PD deficiency and vivax malaria. The current labora-
tory findings lend to making the substantial investments
required to do so.
Inhibiting G6PD activity in intact RBCswith CuCl al-
lowed us to simulate the full range of G6PD activity
phenotypes among hemizygous males and heterozy-
gous females. Capturing such representation among
naturally occurring phenotypes would be highly
impractical, requiring a sample of many tens of thou-
sands among dozens of distinct human populations.
The CuCl model for G6PD deficiency is relatively sim-
ple and inexpensive, requiring no specialty chemicals or
reagents and using only standard laboratory equipment.
We have demonstrated the utility of this model in as-
sessing diagnostic performance of 2 qualitative
screening tests across the full range of possible G6PD
phenotypes. The relative consistency of evenly
decreasing G6PD activity across proportions of RBCs
treated with 1.0 mM CuCl (Fig 5) suggests that this
approach may be superior to variable CuCl concentra-
tion treatments (Fig 4) with respect to evaluating
G6PD diagnostics performance in general. It was also
less laborious.
We considered the diagnosis of G6PD deficiency and
a diagnostic test guiding a decision to administer prima-
quine therapy as 2 distinct clinical objectives. This
distinction is important because the FSTand other qual-
itative tests are well known to be unreliable in the diag-
nosis of G6PD deficiency at residual activities between
30% and 70% of normal.24,25 The findings in this study
corroborated that trend and range. However, the most
threatening acute hemolytic anemia caused by
primaquine occurs among those having the very
lowest levels or G6PD activity, for example, ,10%,
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normal G6PD activity have typically exhibited a mild
and self-limited hemolysis.26-30 The scarcity of such
evidence across the broad heterogeneity of G6PD
activity phenotypes was the basis of applying the
noninferiority analysis in this study—there is no
definitive level of residual G6PD activity dividing
safety vs harm with primaquine therapy.
Noninferiority statistical testing across the tiers of
impaired enzyme levels provided a more thorough
assessment of diagnostic performance. We nonetheless
also analyzed diagnostic performance using the
conventional statistics, choosing 40% of normal G6PD
activity as a reasoned margin of patient safety with
primaquine therapy.
Subjective reading of color intensity imposes pitfalls
in the FST and CSG. Although wholly normal and
conspicuously deficient G6PD phenotypes may be
distinguished with relative ease (see Fig 1), the interme-
diate phenotypes impose real difficulty. We dealt with
this uncertainty by training readers to consider any
test having diminished color development to be posi-
tive, that is, G6PD deficient and ineligible for prima-
quine therapy. Health care workers in the endemic
tropics, we reasoned, would not be trained to make a
classification of intermediate for the simple reason
that such ambiguity defeats the aim of the test—a
‘‘go’’ vs ‘‘no go’’ decision on primaquine therapy. A
classification of intermediate leaves that decision unin-
formed, so it was abandoned in this assessment. We
further reasoned that favoring the classification of pos-
itive represented the appropriately conservative
approach to the decision on primaquine therapy with re-
gard to patient safety.
At intermediate G6PD activities in our experiments,
the subjectivity of reading was most apparent be-
tween 2.75 and 3.5 U/gHb (37%–51% of normal;
see Figs 3–5) with both positive and negative
readings being relatively frequent. Reading with the
CSG as negative in this range proved less likely
than with FST (odds ratio 5 0.44; 95% confidence
interval 5 0.20–0.95; P 5 0.04). We viewed erring
in favor patient safety in this range to be a likely
advantage of CSG over FST, but acknowledge
denying primaquine therapy to any patient who may
safely receive it would also be a poor outcome.
Improving specificity with the CSG could perhaps
be achieved by the availability of a dummy cassette
permanently exhibiting a color representing that
occurring at an intermediate G6PD range, where less
intense color should be considered positive and
more intense color negative for deficiency. Such a
simple device would help guide this difficult
subjective decision by the reader.
Fig 4. Graph illustrates diminishing quantitative G6PD activity (left
y-axis) with increasing concentrations of CuCl treatment (x-axis)
and the proportion of qualitative tests (fluorescent spot test [FST],
solid line and filled circles or CareStart G6PD [CSG], dashed line
and3marks) positive for G6PD deficiency (right y-axis). As in hemi-
zygous states of G6PD deficiency, all red blood cells (RBCs) experi-
ence the effects of CuCl inhibition of G6PD. Hollow circles indicate
quantitative G6PDmeasures defining a mean (solid lateral line) within
boxes of 95% confidence intervals in the observed range of values (T
lines at either end of the boxes).
Fig 5. Graph illustrates diminishing quantitative G6PD activity (left
y-axis) with increasing proportions of 1.0 mM CuCl-treated red blood
cells (RBCs) with untreated RBCs (x-axis) and the proportion of qual-
itative tests (fluorescent spot test [FST], solid line and filled circles or
CareStart G6PD [CSG], dashed line and3 marks) positive for G6PD
deficiency (right y-axis). As in heterozygous states of G6PD defi-
ciency, only CuCl-treated RBCs experience the effects of CuCl inhibi-
tion of G6PD. Hollow circles indicate quantitative G6PD measures
defining a mean (solid lateral line) within boxes of 95% confidence in-
tervals in the observed range of values (T lines at either end of the
boxes).
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diagnostics and primaquine safety. G6PD activity in any
given blood sample represents the consensus activity of
the many individual RBCs present in the sample. The
mosaicism of female heterozygotes for G6PD activity
phenotype among RBCs complicates that representa-
tion and has implications for the primaquine go vs no
go output of a G6DPD diagnostic device. A hypothetical
example illustrates this problem: a female presents a
consensus G6PD activity of 50% of normal, and thus,
she may often test negative for G6PD deficiency despite
up to one half of her RBCs perhaps being fully vulner-
able to primaquine-induced hemolysis.31 The data illus-
trated in Fig 5 affirm this problem. Both the FST and
CSG performed erratically with .30% and ,80% of
RBCs being G6PD inhibited (by 1.0 mM CuCl). The
proportion classified as negative at 50% of normal activ-
ity was approximately 50%. If the G6PD-deficient
RBCs in such patients were indeed fully susceptible,
neither the CSG nor FST would consistently prevent
harmful exposure to primaquine. This problem will
require clinical studies that would carefully assess the
dangers imposed by this vulnerability.
The most severe G6PD deficiency variants appear to
be most commonwhere P. vivax occurs in greatest abun-
dance, in South and Southeast Asia.32 Some evidence
suggests that P. vivax drives selection for G6PD defi-
ciency,33 which would require affecting the reticulo-cytes strictly preferred by this species—natural G6PD
activity decays from the highest level in reticulocytes
as RBCs age. Populations most likely to benefit from
primaquine therapy against relapse may also be at great-
est risk of suffering serious harm caused by it.
Primaquine in G6PD normal patients is remarkably
safe and well tolerated and still exerts superb efficacy
against relapse despite 60 years of continuous use.9,34-
36 The drug provides the enormous clinical benefit of
preventing multiple pernicious and threatening attacks
of acute malaria. Denying people access to this
therapy undoubtedly imposes substantial and
preventable burdens of morbidity and mortality, but
providing it imposes risk of the serious harm.
Practical and robust G6PD diagnostics at the point of
care where most patients with malaria live would
greatly mitigate this dilemma. The findings reported
here suggest that the CSG may be suitable for this
diagnostic task. We detailed a robust means of
assessing G6PD diagnostic devices in the laboratory
with relative ease, simplicity, and low cost.
The availability of G6PD screening in endemic zones
would likely add to the already substantial number of
patients who cannot receive primaquine therapy—preg-
nant or lactating women and infants,37 among the
most vulnerable to serious illness with acute vivax
Translational Research
Volume 165, Number 6 Baird et al 687malaria.38,39 Further, some patients with relatively
common mutations to 2D6 cytochrome P-450 may
remain partially or fully susceptible to relapse despite
primaquine therapy.40 These patients, including those
screened out as G6PD deficient, will require alternative
chemotherapeutic or chemopreventive strategies
against relapse. Conceiving, optimizing, and validating
such approaches should be a very high clinical research
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